UNIGE document Scientific Article
previous document  unige:104794  next document
add to browser collection

Risk of recurrent venous thromboembolism according to baseline risk factor profiles

Prins, Martin H
Lensing, Anthonie W A
Prandoni, Paolo
Wells, Philip S
Verhamme, Peter
Beyer-Westendorf, Jan
Bauersachs, Rupert
show hidden authors show all authors [1 - 18]
Published in Blood Advances. 2018, vol. 2, no. 7, p. 788-796
Abstract The optimal duration of anticoagulation for venous thromboembolism (VTE) is uncertain. In this prespecified analysis, we used data from 2 randomized trials, which compared once-daily rivaroxaban (20 mg or 10 mg) with aspirin (100 mg) or placebo for extended VTE treatment to estimate the risk of recurrence according to baseline risk factor profiles. Index VTE events were centrally classified as unprovoked, or provoked by major transient or persistent, or minor transient or persistent risk factors, and rates of recurrence at 1 year were calculated. A total of 2832 patients received rivaroxaban; 1131 received aspirin, and 590 received placebo. With unprovoked VTE, rates of recurrence in the 1173 patients given rivaroxaban, the 468 given aspirin, and the 243 given placebo were 2.0%, 5.9%, and 10.0%, respectively. There were no recurrences in patients with VTE provoked by major transient risk factors. With VTE provoked by minor persistent risk factors, recurrence rates in the 1184 patients given rivaroxaban, the 466 given aspirin, and the 248 given placebo were 2.4%, 4.5%, and 10.7%, respectively. For patients with minor transient risk factors, recurrence rates were 0.4% in the 268 patients given rivaroxaban, 4.2% in the 121 given aspirin, and 7.1% in the 56 given placebo. Recurrence rates in patients with VTE provoked by minor persistent or minor transient risk factors were not significantly lower than that with unprovoked VTE (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.56-1.16; and HR, 0.68; 95% CI, 0.32-1.30, respectively). Therefore, such patients may also benefit from extended anticoagulation therapy.
PMID: 29632234
Full text
Article (Published version) (749 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group La maladie thromboembolique veineuse (808)
(ISO format)
PRINS, Martin H et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. In: Blood Advances, 2018, vol. 2, n° 7, p. 788-796. doi: 10.1182/bloodadvances.2018017160 https://archive-ouverte.unige.ch/unige:104794

246 hits

0 download


Deposited on : 2018-05-31

Export document
Format :
Citation style :